Related Experiment Video
Updated: May 23, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
TLR2 and TLR4 gene polymorphisms in Turkish vitiligo patients
N Karaca1, G Ozturk, B T Gerceker
1Department of Dermatology, Okmeydanı Education and Research Hospital, Istanbul, Turkey.
Summary
Toll-like receptor (TLR) gene polymorphisms, specifically TLR2 Arg753Gln and TLR4 Asp299Gly, are associated with increased vitiligo susceptibility in Turkish patients. These findings suggest a role for these TLRs in the inflammatory pathways contributing to vitiligo development.
Area of Science:
- Immunogenetics
- Dermatology
- Genetic Epidemiology
Background:
- Toll-like receptors (TLRs) are implicated in inflammatory skin conditions like psoriasis and atopic dermatitis.
- Vitiligo, an acquired pigmentation disorder, has an unknown etiology, but inflammatory genes may play a role.
- Genetic variations in TLRs could influence susceptibility to vitiligo.
Purpose of the Study:
- To investigate the association between Toll-like receptor 2 (TLR2) and Toll-like receptor 4 (TLR4) gene polymorphisms and vitiligo in a Turkish population.
- To determine if specific TLR2 and TLR4 genotypes are risk factors for developing vitiligo.
Main Methods:
- Genotyping of TLR2 Arg753Gln and TLR4 Asp299Gly/Thr399Ile polymorphisms using polymerase chain reaction and restriction fragment length polymorphism.
- Study included 100 vitiligo patients and 100 healthy controls from Turkey.
- Statistical analysis involved Mann-Whitney U-test, chi-squared test, and logistic regression.
Main Results:
- A significant difference in TLR2 Arg753Gln genotype distribution and TLR2 753Gln allele frequencies was observed between vitiligo patients and controls (P < 0.05).
- The TLR4 Asp299Gly genotype was significantly more prevalent in vitiligo patients (10%) compared to controls (2%) (P < 0.05).
- No significant difference in TLR4 Thr399Ile distribution was found between the groups.
Conclusions:
- The study suggests that TLR2 Arg753Gln and TLR4 Asp299Gly gene polymorphisms are associated with susceptibility to vitiligo in the Turkish population.
- These findings highlight the potential role of specific TLR gene variants in the pathogenesis of vitiligo.
- Further research may explore the functional implications of these genetic associations in vitiligo.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...